CHMP5 and COVID-19: This finding is consistent with the use of IL‐6 receptor antagonists, including Tocilizumab and Sarilumab, to improve outcomes and survival in critically ill patients with COVID‐19.[50, 51, 52] In addition, we created custom‐designed nanoparticles conjugated with hACE2 as a decoy for the SARS‐CoV‐2 Spike protein, and we demonstrated that Lipo‐hACE2 inhibited microthrombosis in the presence of the Spike, the D614G variant and the live SARS‐CoV‐2.